Strides announces nod from Equity shareholders, secured creditors for creation of OneSource
Bangalore: Strides Pharma Science Limited has announced that it
has secured the approval of its equity shareholders and secured creditors with overwhelming majority, along
with those of OneSource Specialty Pharma Limited and SteriScience Specialties Private Limited, in meetings
convened under the guidance of the Hon’ble National Company Law Tribunal (NCLT). All the secured
creditors who voted on the Scheme for the three Companies in their respective meetings, were in favour of
the Scheme.
“This is a critical step in the creation of OneSource and the support from Shareholders and Secured Creditors
underscores the confidence in the Company’s strategic initiative to create OneSource – India’s first specialty
pharma Contract Development and Manufacturing Organization (CDMO) covering advanced sectors like
biologics, complex injectables, and oral technologies, including soft-gelatin capsules,” the company informed in a release.
In September 2023, Strides announced its strategic initiative to create OneSource as an Independent
Specialty Pharma CDMO by integrating the Oral Technologies (Soft Gelatin Capsules) business from Strides,
Sterile Injectables business of SteriScience Specialty Private Limited and the Biologics and high-end drug
devices combination business of OneSource (erstwhile Stelis).
“Having already received Stock Exchange approvals in May 2024, this latest approval from Equity
Shareholders and Secured Creditors marks a significant milestone. The Company will now seek final approval
from the Hon’ble NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing
approvals from the BSE and NSE”, the Company stated.
Commenting on the development, Mr Arun Kumar, Executive Chairperson and Mr. Badree Komandur,
Managing Director and Group CEO stated, “We are pleased to have received strong backing from our
shareholders and secured creditors for the creation of OneSource. We believe OneSource will unlock
considerable value for Strides’ stakeholders upon its listing. We remain committed to delivering on this
promise and express our gratitude to our shareholders and creditors for their continued trust and support.”
Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited
(532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the
regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donorfunded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and
two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company
focuses on “difficult to manufacture” products sold in over 100 countries. Additional information is available
at the Company’s website at www.strides.com.
Also Read: USFDA approves Strides Pharma Global stomach ulcer treatment drug
